Phibro Animal Health Declares Quarterly Dividend of $0.12 Per Share

Dividend Payment Details and Timeline

Phibro Animal Health Corporation disclosed that the quarterly cash dividend has been set at $0.12 per share. The filing states that this dividend applies to both the company's Class A common stock and Class B common stock, ensuring that all common stockholders receive equal treatment on a per-share basis. The record date for determining eligibility to receive the dividend is September 2, 2026, at the close of business. Stockholders who own shares on this date will be entitled to receive the dividend payment.

The actual payment of the dividend is scheduled for September 23, 2026. This timeline provides approximately three weeks between the record date and payment date, allowing the company's transfer agent and payment processor adequate time to process and distribute funds to eligible shareholders. Investors holding the stock before the record date will need to maintain their positions through that date to qualify for this quarterly payment.

Application to Class A and Class B Common Stock

The disclosure indicates that the $0.12 per share dividend applies uniformly to both the Class A common stock and the Class B common stock issued by Phibro Animal Health. This equal treatment suggests that the company maintains a consistent dividend policy across its two share classes, which is a standard practice for many publicly traded corporations. The Class A common stock is the primary security trading on the NASDAQ under the ticker symbol PAHC.

The announcement does not differentiate between the two share classes in terms of dividend treatment, indicating that holders of either class will receive the same per-share amount. This approach simplifies the company's dividend administration and signals equal consideration for both equity classes in the capital allocation decision. Investors tracking their dividend income should note this parity in calculating expected quarterly returns from their Phibro Animal Health shareholdings.

Company Background and Market Position

Phibro Animal Health Corporation is a Delaware-incorporated company headquartered in Teaneck, New Jersey, with its principal executive offices located at Glenpointe Centre East, 3rd Floor, 300 Frank W. Burr Boulevard. The company operates in the animal health sector and maintains a listing on the NASDAQ stock exchange under the Class A common stock ticker PAHC. The filing indicates the company's IRS Employer Identification Number is 13-1840497 and its SEC Commission File Number is 01-36410.

As a NASDAQ-listed corporation, Phibro Animal Health is subject to the full regulatory requirements of the Securities Exchange Act of 1934 and other applicable securities laws. The company's status as a reporting company means it must file periodic disclosures with the Securities and Exchange Commission and maintain compliance with stock exchange listing standards. The dividend declaration represents one component of the company's corporate governance and shareholder return strategy.

Shareholder Communication and Disclosure Process

The announcement of the quarterly dividend was made through an official press release issued on July 28, 2026, the same date as the board's declaration. Phibro Animal Health filed this Current Report to provide formal notification to investors and the public of the dividend decision. The press release was included as an exhibit to the filing, ensuring that the full details and context of the announcement are available to investors reviewing company disclosures with the Securities and Exchange Commission.

The filing was signed by Judith Weinstein, identified as Senior Vice President, General Counsel and Corporate Secretary, on July 28, 2026. This executive's authorization of the filing demonstrates the formal approval chain within the company for significant shareholder communications. The use of a Current Report for this announcement reflects the securities law requirement to promptly disclose material corporate events, including significant dividend decisions, to the investing public.

Capital Allocation Strategy Reflected in Dividend Policy

The declaration of a quarterly cash dividend at $0.12 per share indicates that Phibro Animal Health's board of directors continues to view returning capital to shareholders as an appropriate use of company resources. Regular quarterly dividend payments demonstrate a commitment to providing ongoing income to equity holders alongside any potential share price appreciation. This strategy is typical among mature, cash-generating companies in the animal health and specialty pharmaceutical sectors.

The decision to maintain a dividend payment schedule reflects management's confidence in the company's financial condition and cash flow generation capabilities. Companies that declare regular dividends typically do so when they believe they can sustain such payments while funding operations, investing in growth opportunities, and maintaining appropriate capital reserves. The consistency of the quarterly dividend payment serves as a signal to investors about the company's financial stability and shareholder-friendly capital allocation approach.

Regulatory Framework and Reporting Requirements

The filing of this Current Report follows the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934. Phibro Animal Health is required to disclose material events and corporate actions to investors in a timely manner through regulatory filings. The dividend declaration qualifies as a material corporate event requiring disclosure, as it directly affects shareholder value and income. The company elected to file under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), providing the necessary documentation of the board's action.

The company is not classified as an emerging growth company based on the disclosure in the filing. This status means Phibro Animal Health is subject to the full range of SEC reporting requirements and compliance obligations without access to certain transition periods or scaled disclosure provisions available to emerging growth companies. The filing includes standard certifications regarding the form's accuracy and completeness, executed by an authorized company officer.

Implications for Investors Monitoring Phibro Animal Health

Investors who hold or are considering holding Phibro Animal Health stock should note the record date of September 2, 2026, if they wish to receive the declared quarterly dividend. Stock purchases made after the record date will not entitle the buyer to this particular dividend payment; instead, the seller as of the record date will be entitled to receive it. Conversely, investors who own the stock on September 2, 2026, will automatically be entitled to receive the $0.12 per share dividend on September 23, 2026, regardless of whether they continue to hold the shares after the record date.

The immediate share price impact was not clear from available public information. The filing itself does not contain forward-looking guidance regarding the company's financial performance, earnings expectations, or plans for future dividends. Investors analyzing the dividend decision should consider it in the context of the company's overall financial results, free cash flow generation, and competitive position within the animal health industry. Tracking changes in quarterly dividend amounts over time can provide insight into management's view of the company's financial trajectory.

Documentation and File References

The press release announcing the dividend declaration was filed as Exhibit 99.1 to the Current Report and is incorporated by reference in the filing. This means that investors seeking additional details or context regarding the dividend announcement should review the press release document, which is publicly available through the SEC's EDGAR filing system. The filing also includes an Interactive Data File (Exhibit 104) formatted in Inline XBRL, which presents the cover page information in machine-readable format for enhanced accessibility and analysis.

All documents related to this announcement, including the press release and the Current Report itself, are available on the SEC's EDGAR database under Phibro Animal Health Corporation's CIK number 0001069899. Investors and analysts may access these documents at no cost through the SEC website. The filing provides a complete record of the board's dividend declaration and the company's formal notification to shareholders and the public.